Please login to the form below

Not currently logged in
Email:
Password:

TAK-003

This page shows the latest TAK-003 news and features for those working in and with pharma, biotech and healthcare.

Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

Dengue vaccine TAK-003:Takeda’s dengue fever vaccine candidate  TAK-003 hit the efficacy mark in a large-scale study reported earlier this month, and seems to be safe in ... In September, it presented proof-of-concept data suggesting one candidate –

Latest news

  • Takeda’s dengue vaccine seems safe with no prior virus exposure Takeda’s dengue vaccine seems safe with no prior virus exposure

    Appears unaffected by serious safety issue affecting Sanofi rival. Takeda says new data shows its candidate vaccine for dengue fever TAK-003 is effective, and crucially doesn’t seem to be ... It’s also investing in production capacity for TAK-003,

  • Sanofi confirms suspected safety issue with dengue vaccine Sanofi confirms suspected safety issue with dengue vaccine

    The setbacks for Dengvaxia provide an opportunity for rival Takeda to leapfrog Sanofi with its own dengue vaccine candidate TAK-003, which has showed a higher rate of protective efficacy in ... Industry watchers have suggested TAK-003 could be on the

  • Takeda dengue vaccine data looks good as it chases Sanofi Takeda dengue vaccine data looks good as it chases Sanofi

    TAK-003 achieved a 71% reduction in developing the virus compared to placebo. ... The reduced incidence of dengue in children and adolescents receiving TAK-003 is encouraging, however data from our ongoing Phase 3 efficacy trial, TIDES, are required to

  • Takeda plans German plant to support dengue vaccine roll-out Takeda plans German plant to support dengue vaccine roll-out

    The plant in Singen is a "major step towards meeting important unmet needs in dengue prevention," according to the Japanese drugmaker, which recently started a phase III trial of its ... Takeda started its phase III TIDES trial of the live-attenuated

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics